A Phase 1 interventional study of [14C]-PC14586 in Healthy Male Volunteers, sponsored by PMV Pharmaceuticals, Inc. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-12-20.
Sponsored by PMV Pharmaceuticals, Inc · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will assess the PK and rates of elimination and mass balance of total radioactivity from [14C]-PC14586
PC14586 is a first-in-class, oral, small molecule p53 reactivator that is selective for the TP53 Y220C mutation. The study will assess the PK, absorption, metabolism, and excretion of [14C]-PC14586 following a single dose in healthy male participants.
The aim is to recruit approximately 8 participants with a minimum number of 6 evaluable participants.
Each participant will be admitted to the study site pre-dose on Day -1 and will remain at the study site until at least Day 14. Participants will receive a single administration of [14C]-PC14586 as oral capsules on Day 1. During this study, whole blood, plasma, urine, feces, and vomit samples (if presented) will be collected at various timepoints to characterize the absorption, metabolism, excretion, and PK of [14C]-PC14586.
The duration of the residential period will be evaluated following the administration of [14C]-PC14586 and may be extended to ensure recovery of at least 90% of the total radioactivity, or until less than 1% of dose is recovered in urine and/or feces.
PMV Pharmaceuticals, Inc is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy, male participants will receive a single, oral dose of \[14C\]-PC14586
Drug: [14C]-PC14586
Single, oral dose of \[14C\]-PC14586
Characterize Maximum Plasma Concentration (Cmax) of PC14586 and PC14586 metabolite M1 (PC16163).
Determine Cmax for PC14586 and PC16163 in plasma.
Time frame: 1 month
Characterize Time to Maximum Plasma Concentration (tmax) of PC14586 and PC14586 metabolite M1 (PC16163).
Determine tmax for PC14586 and PC16163 in plasma.
Time frame: 1 month
Characterize Total Drug Exposure (AUC0-inf) of PC14586 and PC14586 metabolite M1 (PC16163).
Determine AUC0-inf for PC14586 and PC16163 in plasma.
Time frame: 1 month
Characterize Total Drug Exposure to the last measurable concentration (AUC0-t) of PC14586 and PC14586 metabolite M1 (PC16163).
Determine AUC0-t for PC14586 and PC16163 in plasma.
Time frame: 1 month
Characterize the Half-Life (t 1/2) of PC14586 and PC14586 metabolite M1 (PC16163).
Determine t 1/2 for PC14586 and PC16163 in plasma.
Time frame: 1 month
Characterize the Clearance (CL/F) of PC14586 and PC14586 metabolite M1 (PC16163) after oral administration.
Determine CL/F for PC14586 and PC16163 in plasma.
Time frame: 1 month
Characterize the Volume of Distribution (Vd/F) of PC14586 and PC14586 metabolite M1 (PC16163) after oral administration.
Determine Vd/F for PC14586 and PC16163 in plasma.
Time frame: 1 month
Determine the total radioactivity in whole blood and plasma of PC14586 and PC14586 metabolite M1 (PC16163).
Determine total radioactivity for PC14586 and PC16163 in whole blood and plasma.
Time frame: 1 month
Characterize total radioactivity (Xlast, feces) of PC14586 excreted in feces.
Determine total radioactivity of PC14586 excreted in feces
Time frame: 1 month
Characterize the half life of total radioactivity (Xt1-t2, feces) of PC14586 excreted in feces.
Determine half life of total radioactivity of PC14586 excreted in feces.
Time frame: 1 month
Characterize the fraction excreted of total radioactivity (fe last, feces) of PC14586 in feces.
Determine the fraction excreted of total radioactivity of PC14586 in feces.
Time frame: 1 month
Characterize the half-life of fraction excreted of total radioactivity (fe t1-t2, feces) of PC14586 in feces.
Determine half-life of fraction excreted of total radioactivity of PC14586 in feces.
Time frame: 1 month
Characterize total radioactivity (Xlast, urine) of PC14586 excreted in urine.
Determine total radioactivity of PC14586 excreted in urine.
Time frame: 1 month
Characterize the half life of total radioactivity (Xt1-t2, urine) of PC14586 excreted in urine.
Determine half life of total radioactivity of PC14586 excreted in urine.
Time frame: 1 month
Characterize the fraction excreted of total radioactivity (fe last, urine) of PC14586 in urine.
Determine the fraction excreted of total radioactivity of PC14586 in urine.
Time frame: 1 month
Characterize the half-life of fraction excreted of total radioactivity (fe t1-t2, urine) of PC14586 in urine.
Determine half-life of fraction excreted of total radioactivity of PC14586 in urine.
Time frame: 1 month
Characterize the renal clearance (CLr) of PC14586 in urine.
Determine the renal clearance of PC14586 in urine.
Time frame: 1 month
Identification of PC14586 metabolite profiles in plasma, urine and feces.
Identification of PC14586 metabolites in plasma (\>10% relative total drug related exposure) and excreta (\>10% of excreted dose).
Time frame: 1 month
Identification of the incidence and severity of adverse events after administration of PC14586.
Number of participants with adverse events.
Time frame: 1 month
Identification of the incidence of laboratory abnormalities based on hematology, clinical chemistry and urine test results of PC14586.
Number of participants with an incidence of laboratory abnormalities in test results.
Time frame: 1 month
Identification of 12-lead electrocardiogram (ECG) abnormalities after a single dose of PC14586.
Number of participants with abnormal 12-lead ECG results.
Time frame: 1 month
Identification of abnormal blood pressure after a single dose of PC14586.
Number of participants with abnormal blood pressure.
Time frame: 1 month
Identification of abnormal pulse rate after a single dose of PC14586.
Number of participants with abnormal pulse rate.
Time frame: 1 month
Identification of abnormal oral body temperature after a single dose of PC14586.
Number of participants with abnormal oral body temperature.
Time frame: 1 month
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2022 to primary completion in Nov 2022, 2 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rezatapopt
PMV Pharmaceuticals, Inc